A citation-based method for searching scientific literature

D A Stoffers, T J Kieffer, M A Hussain, D J Drucker, S Bonner-Weir, J F Habener, J M Egan. Diabetes 2000
Times Cited: 453







List of co-cited articles
1115 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Yazhou Li, Tanya Hansotia, Bernardo Yusta, Frederic Ris, Philippe A Halban, Daniel J Drucker. J Biol Chem 2003
464
18

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.
Loredana Farilla, Hongxiang Hui, Cristina Bertolotto, Elizabeth Kang, Angela Bulotta, Umberto Di Mario, Riccardo Perfetti. Endocrinology 2002
380
18

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.
Loredana Farilla, Angela Bulotta, Boaz Hirshberg, Sergio Li Calzi, Nasif Khoury, Houtan Noushmehr, Cristina Bertolotto, Umberto Di Mario, David M Harlan, Riccardo Perfetti. Endocrinology 2003
473
17


Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.
D J Drucker, J Philippe, S Mojsov, W L Chick, J F Habener. Proc Natl Acad Sci U S A 1987
619
17


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
14



The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
14


The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
12

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
540
12



Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
11

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
Bidda Rolin, Marianne O Larsen, Carsten F Gotfredsen, Carolyn F Deacon, Richard D Carr, Michael Wilken, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2002
236
11



beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
Yazhou Li, Xiemin Cao, Li-Xin Li, Patricia L Brubaker, Helena Edlund, Daniel J Drucker. Diabetes 2005
151
10


Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.
J S Nachnani, D G Bulchandani, A Nookala, B Herndon, A Molteni, P Pandya, R Taylor, T Quinn, L Weide, L M Alba. Diabetologia 2010
139
9

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
663
9

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
920
9

Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat.
Doris A Stoffers, Biva M Desai, Diva D DeLeon, Rebecca A Simmons. Diabetes 2003
195
9


A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
8


Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
M A Nauck, U Niedereichholz, R Ettler, J J Holst, C Orskov, R Ritzel, W H Schmiegel. Am J Physiol 1997
512
8

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.
L A Scrocchi, T J Brown, N MaClusky, P L Brubaker, A B Auerbach, A L Joyner, D J Drucker. Nat Med 1996
576
8

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
727
8

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
8


Stimulation of insulin secretion by gastric inhibitory polypeptide in man.
J Dupre, S A Ross, D Watson, J C Brown. J Clin Endocrinol Metab 1973
706
8

GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress.
Bernardo Yusta, Laurie L Baggio, Jennifer L Estall, Jackie A Koehler, Dianne P Holland, Hongyun Li, Danny Pipeleers, Zhidong Ling, Daniel J Drucker. Cell Metab 2006
285
8



Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
8

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
Jeppe Sturis, Carsten F Gotfredsen, John Rømer, Bidda Rolin, Ulla Ribel, Christian L Brand, Michael Wilken, Karsten Wassermann, Carolyn F Deacon, Richard D Carr,[...]. Br J Pharmacol 2003
159
8

Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Máire E Doyle, Josephine M Egan. Pharmacol Ther 2007
398
8

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang,[...]. J Clin Endocrinol Metab 2003
421
7

Expression of the GLP-1 receptor in mouse, rat, and human pancreas.
Ditte Tornehave, Peter Kristensen, John Rømer, Lotte Bjerre Knudsen, R Scott Heller. J Histochem Cytochem 2008
167
7

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Niels C B Nyborg, Anne-Marie Mølck, Lars W Madsen, Lotte Bjerre Knudsen. Diabetes 2012
103
7



Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
717
7


Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.
J Buteau, S Foisy, C J Rhodes, L Carpenter, T J Biden, M Prentki. Diabetes 2001
192
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.